Operational Costs Compared: SG&A Analysis of Novartis AG and argenx SE

A Decade of SG&A: Novartis AG vs. argenx SE

In the ever-evolving pharmaceutical landscape, operational efficiency is paramount. Over the past decade, Novartis AG and argenx SE have showcased contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. Novartis, a Swiss giant, consistently reported SG&A expenses averaging around $14.5 billion annually, peaking in 2018. In contrast, Belgian biotech firm argenx SE, with its innovative therapies, saw a staggering 16,600% increase in SG&A from 2014 to 2023, reflecting its rapid growth and market expansion.

Key Insights

• Novartis AG: Despite fluctuations, Novartis maintained a steady SG&A trend, indicating robust operational strategies.
• argenx SE: The exponential rise in SG&A expenses underscores its aggressive market penetration and scaling efforts.

This analysis highlights the strategic financial maneuvers of two distinct players in the pharmaceutical sector, offering insights into their operational priorities and market dynamics.